Product Description: Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine[1]. Rovalpituzumab has activity against small cell lung cancer (SCLC)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Bilal H Lashari, et al. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate. Drugs R D. 2018 Dec;18(4):255-258.